Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL AUTOMATED AND RAPID MICROBIOLOGICAL TESTS INDUSTRY
2.1 Summary about Automated And Rapid Microbiological Tests Industry
2.2 Automated And Rapid Microbiological Tests Market Trends
2.2.1 Automated And Rapid Microbiological Tests Production & Consumption Trends
2.2.2 Automated And Rapid Microbiological Tests Demand Structure Trends
2.3 Automated And Rapid Microbiological Tests Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Automated Identification & Susceptibility Systems
4.2.2 Automated Blood Culture Systems
4.2.3 Automated Tuberculosis Systems
4.2.4 Streptococcal Infection Rapid Tests
4.2.5 GC/Chlamydia Rapid Tests
4.2.6 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Clinical
4.3.2 Non-Clinical
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Automated Identification & Susceptibility Systems
5.2.2 Automated Blood Culture Systems
5.2.3 Automated Tuberculosis Systems
5.2.4 Streptococcal Infection Rapid Tests
5.2.5 GC/Chlamydia Rapid Tests
5.2.6 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Clinical
5.3.2 Non-Clinical
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Automated Identification & Susceptibility Systems
6.2.2 Automated Blood Culture Systems
6.2.3 Automated Tuberculosis Systems
6.2.4 Streptococcal Infection Rapid Tests
6.2.5 GC/Chlamydia Rapid Tests
6.2.6 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Clinical
6.3.2 Non-Clinical
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Automated Identification & Susceptibility Systems
7.2.2 Automated Blood Culture Systems
7.2.3 Automated Tuberculosis Systems
7.2.4 Streptococcal Infection Rapid Tests
7.2.5 GC/Chlamydia Rapid Tests
7.2.6 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Clinical
7.3.2 Non-Clinical
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Automated Identification & Susceptibility Systems
8.2.2 Automated Blood Culture Systems
8.2.3 Automated Tuberculosis Systems
8.2.4 Streptococcal Infection Rapid Tests
8.2.5 GC/Chlamydia Rapid Tests
8.2.6 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Clinical
8.3.2 Non-Clinical
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Automated Identification & Susceptibility Systems
9.2.2 Automated Blood Culture Systems
9.2.3 Automated Tuberculosis Systems
9.2.4 Streptococcal Infection Rapid Tests
9.2.5 GC/Chlamydia Rapid Tests
9.2.6 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Clinical
9.3.2 Non-Clinical
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Abbott Laboratories
10.1.2 Abbott Diagnostics, Alere Inc.
10.1.3 Becton Dickinson and Company
10.1.4 bioMerieux SA, bioMerieux, Inc.
10.1.5 Bio-Rad Laboratories, Inc.
10.1.6 Cellabs Pty Ltd,
10.1.7 Celsis International Plc.
10.1.8 Coris BioConcept, F. Hoffmann-La Roche Ltd.
10.1.9 Gen-Probe Inc.
10.1.10 Genzyme Diagnostics
10.1.11 MedMira Inc.
10.1.12 Meridian Biosciences, Inc.
10.1.13 Orasure Technologies, Inc.
10.1.14 Orion Diagnostica Oy
10.1.15 Quidel Corporation
10.1.16 Siemens Healthcare Diagnostics, Inc.
10.1.17 Thermo Fisher Scientific, Inc.
10.1.18 Remel, Inc.
10.1.19 Oxoid Limited
10.2 Automated And Rapid Microbiological Tests Sales Date of Major Players (2017-2020e)
10.2.1 Abbott Laboratories
10.2.2 Abbott Diagnostics, Alere Inc.
10.2.3 Becton Dickinson and Company
10.2.4 bioMerieux SA, bioMerieux, Inc.
10.2.5 Bio-Rad Laboratories, Inc.
10.2.6 Cellabs Pty Ltd,
10.2.7 Celsis International Plc.
10.2.8 Coris BioConcept, F. Hoffmann-La Roche Ltd.
10.2.9 Gen-Probe Inc.
10.2.10 Genzyme Diagnostics
10.2.11 MedMira Inc.
10.2.12 Meridian Biosciences, Inc.
10.2.13 Orasure Technologies, Inc.
10.2.14 Orion Diagnostica Oy
10.2.15 Quidel Corporation
10.2.16 Siemens Healthcare Diagnostics, Inc.
10.2.17 Thermo Fisher Scientific, Inc.
10.2.18 Remel, Inc.
10.2.19 Oxoid Limited
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT